How Much Muscle vs Fat Do You Actually Lose on GLP-1 Drugs Compared to Bariatric Surgery?

Over 24 months, both bariatric surgery and GLP-1 drugs (semaglutide/tirzepatide) produced substantial fat loss and moderate lean mass loss, but surgery was dramatically more effective. Surgery patients lost 49.7% of their fat mass versus 18.0% for GLP-1RA patients at 24 months. Lean mass loss was 11.7% with surgery versus 3.3% with GLP-1 drugs. Crucially, both groups improved their lean-to-fat ratio — meaning the weight lost was predominantly fat, not muscle. The lean-to-fat ratio improved to 2.0 with surgery and 1.5 with GLP-1 drugs at 24 months. Men preserved lean mass better than women, especially on GLP-1 drugs.

Retrospective cohort study using electronic health records from Vanderbilt University Medical Center. 1,257 bariatric surgery patients and 1,809 GLP-1RA patients (semaglutide or tirzepatide) were followed for up to 24 months. Body composition was measured by bioelectrical impedance analysis at 2+ timepoints. Results were adjusted for age, sex, race, baseline BMI, diabetes status, treatment year, and time.

One of the biggest concerns about GLP-1 weight-loss drugs is that they cause excessive muscle loss ("Ozempic body"). This large real-world study provides reassuring data: while both surgery and GLP-1 drugs do cause some lean mass loss, the ratio of fat-to-lean mass lost is favorable in both cases. The lean-to-fat ratio actually improved, meaning patients became proportionally leaner. This is the largest real-world body composition comparison between bariatric surgery and modern GLP-1 drugs.

The "Ozempic body" concern — that GLP-1 drugs cause disproportionate muscle loss — has been a persistent media narrative. This large real-world study suggests the concern is somewhat overblown: while lean mass loss does occur, it's proportionally small compared to fat loss, and the overall body composition improves. However, the study also highlights that surgery still vastly outperforms drugs in terms of total fat reduction, which is important context for patients choosing between approaches.

This is a retrospective observational study, not a randomized trial — the surgery and GLP-1RA groups differed in baseline characteristics (surgery patients had higher mean BMI: 46.8 vs 41.0). Single-center data from Vanderbilt may not generalize to all populations. Bioelectrical impedance analysis is less precise than DEXA for measuring body composition. The GLP-1RA group included both semaglutide and tirzepatide, which may have different body composition effects.